Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€71.05

€71.05

1.430%
1.0
1.430%
€93.50

€93.50

 
Latest predictions
€100.00
13.07.20
buy
€87.00
10.12.19
buy
Your prediction

Ipsen S.A. Stock

Ipsen S.A. gained 1.430% today.
The community is currently still undecided about Ipsen S.A. with 2 Buy predictions and 0 Sell predictions.
With a target price of €93.00 there is a positive potential of 30.894% for Ipsen S.A. compared to the current price of €71.05.

Pros and Cons of Ipsen S.A. in the next few years

Pros
?
Worthwhile Investment for the next years
?
Brand
?
Growth compared to competition
Cons
?
Market Position
?
Shareholder structure
?
Conscious of the environment
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Ipsen S.A. vs. its peers

Security Change (%) 1w 1m 1y YTD 3y 5y
Ipsen S.A. 1.430% 2.304% 0.566% -13.774% 3.950% -36.135% 20.792%
Sanofi S.A. -0.060% 1.986% 2.670% -11.930% 2.411% 11.534% 12.148%
BioMarin Pharmaceutical Inc. 0.710% 3.186% -4.868% -13.418% -1.598% -6.784% -9.308%
Abbott Laboratories 0.220% 0.921% 3.393% 14.722% 4.189% 90.145% 147.047%

Comments

Published 10.12.19
Prediction Buy
Perf. (%) -9.94%
Target price 87.000
Change

Buy with target price 87.0

Published 27.03.12
Prediction Buy
Perf. (%) 6.57%
Target price 21.000
Change

(Zielkurs erreicht)

Published 01.03.12
Prediction Buy
Perf. (%) 6.57%
Target price 21.000
Change

Kauf für Rebound

Die Ergebnisse sind in und der Preis ist gesunken, aber der Wert überverkauft ist und wird daher bald steigen.

Other discussions about Ipsen S.A. Stock

New thread Forum

News

ESMO 2020: Cabometyx® (cabozantinib) in Combination With Opdivo® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial


Regulatory News:



Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which Cabometyx® (cabozantinib) in

Ipsen to Present Results From MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP), at ASBMR 2020 Annual Meeting


Ipsen (Euronext: IPN; ADR: IPSEY) today announced results from the MOVE trial, the first and only multicenter Phase III study in fibrodysplasia ossificans progressiva (FOP), to be presented during